Targeted therapy of multiple myeloma

Multiple myeloma (MM) is a malignant proliferative disease of monoclonal plasma cells (PCs) and is characterized by uncontrolled proliferation of PCs and excessive production of specific types of immunoglobulins. Since PCs are terminally differentiated B cells, the World Health Organization (WHO) cl...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shan Zhou, Renxi Wang
Formato:	article
Lenguaje:	EN
Publicado:	Open Exploration Publishing Inc. 2021
Materias:	multiple myeloma targeted therapy potential targets immune-based therapies precision medicine Internal medicine RC31-1245
Acceso en línea:	https://doaj.org/article/52c45691c8d9471199f1baa11f339240
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:52c45691c8d9471199f1baa11f339240
record_format	dspace
spelling	oai:doaj.org-article:52c45691c8d9471199f1baa11f3392402021-11-08T10:01:05ZTargeted therapy of multiple myeloma10.37349/etat.2021.000572692-3114https://doaj.org/article/52c45691c8d9471199f1baa11f3392402021-10-01T00:00:00Zhttps://www.explorationpub.com/Journals/etat/Article/100257https://doaj.org/toc/2692-3114Multiple myeloma (MM) is a malignant proliferative disease of monoclonal plasma cells (PCs) and is characterized by uncontrolled proliferation of PCs and excessive production of specific types of immunoglobulins. Since PCs are terminally differentiated B cells, the World Health Organization (WHO) classifies MM as lymphoproliferative B-cell disease. The incidence of MM is 6–7 cases per 100,000 people in the world every year and the second most common cancer in the blood system. Due to the effects of drug resistance and malignant regeneration of MM cells in the microenvironment, all current treatment methods can prolong both overall and symptom-free survival rates of patients with MM but cannot cure MM. Both basic and clinical studies have proven that targeted therapy leads to a clear and significant prolongation of the survival of patients with MM, but when the disease recurs again, resistance to the previous treatment will occur. Therefore, the discovery of new targets and treatment methods plays a vital role in the treatment of MM. This article introduces and summarizes targeted MM therapy, potential new targets, and future precision medicine in MM.Shan ZhouRenxi WangOpen Exploration Publishing Inc.articlemultiple myelomatargeted therapypotential targetsimmune-based therapiesprecision medicineInternal medicineRC31-1245ENExploration of Targeted Anti-tumor Therapy, Vol 2, Iss 5, Pp 465-480 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	multiple myeloma targeted therapy potential targets immune-based therapies precision medicine Internal medicine RC31-1245
spellingShingle	multiple myeloma targeted therapy potential targets immune-based therapies precision medicine Internal medicine RC31-1245 Shan Zhou Renxi Wang Targeted therapy of multiple myeloma
description	Multiple myeloma (MM) is a malignant proliferative disease of monoclonal plasma cells (PCs) and is characterized by uncontrolled proliferation of PCs and excessive production of specific types of immunoglobulins. Since PCs are terminally differentiated B cells, the World Health Organization (WHO) classifies MM as lymphoproliferative B-cell disease. The incidence of MM is 6–7 cases per 100,000 people in the world every year and the second most common cancer in the blood system. Due to the effects of drug resistance and malignant regeneration of MM cells in the microenvironment, all current treatment methods can prolong both overall and symptom-free survival rates of patients with MM but cannot cure MM. Both basic and clinical studies have proven that targeted therapy leads to a clear and significant prolongation of the survival of patients with MM, but when the disease recurs again, resistance to the previous treatment will occur. Therefore, the discovery of new targets and treatment methods plays a vital role in the treatment of MM. This article introduces and summarizes targeted MM therapy, potential new targets, and future precision medicine in MM.
format	article
author	Shan Zhou Renxi Wang
author_facet	Shan Zhou Renxi Wang
author_sort	Shan Zhou
title	Targeted therapy of multiple myeloma
title_short	Targeted therapy of multiple myeloma
title_full	Targeted therapy of multiple myeloma
title_fullStr	Targeted therapy of multiple myeloma
title_full_unstemmed	Targeted therapy of multiple myeloma
title_sort	targeted therapy of multiple myeloma
publisher	Open Exploration Publishing Inc.
publishDate	2021
url	https://doaj.org/article/52c45691c8d9471199f1baa11f339240
work_keys_str_mv	AT shanzhou targetedtherapyofmultiplemyeloma AT renxiwang targetedtherapyofmultiplemyeloma
_version_	1718442713380028416

Targeted therapy of multiple myeloma

Ejemplares similares